Article
Author(s):
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
FDA Announces Ramifications of Government Shutdown Due to 2026 Lapse in Funding
Pharmaceutical Executive Daily: Novo Nordisk Resubmits BLA for Awiqli
AI and R&D: From the Eyes of an Entrepreneur
Pharmaceutical Executive Daily: September 29, 2025
Novartis’ Chronic Spontaneous Urticaria Treatment Rhapsido Receives FDA Approval
Halozyme Enters $750 Million Definitive Agreement with Elektrofi Aiming to Expand Drug Delivery and Bolster Long-Term Growth